Basis of Presentation and Accounting Policies - Narrative (Details) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Mar. 31, 2026 |
Sep. 30, 2025 |
Mar. 31, 2025 |
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
| Research and development expense | $ 180 | $ 162 | $ 352 | $ 318 | |
| Cost of sales | (1,114) | $ (1,029) | (2,203) | $ (2,032) | |
| Goodwill, impairment loss | $ 161 | ||||
| Intangible asset impairment charges | 63 | ||||
| Allowance for doubtful accounts | $ 18 | $ 21 | $ 18 | ||
| Antidilutive share-based compensation awards (in shares) | 0.2 | 0.6 | 0.6 | 1.3 | |
| Capital expenditures in accounts payable or other current liabilities at period end | $ 30 | $ 19 | |||
| Outstanding purchase of common stock recorded in accounts payable | $ 12 | $ 3 | $ 12 | 3 | |
| Revision of Prior Period, Reclassification, Adjustment | |||||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
| Research and development expense | 162 | 318 | |||
| Cost of sales | $ 162 | $ 318 | |||
| X | ||||||||||
- Definition This element represents the value of stock that has been repurchased during the period but did not settle until after the period end. No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Future cash outflow to pay for purchases of fixed assets that have occurred. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|